Given the immune-inhibitory function of PDL1 and the immune-activated state portended by increasing tumor infiltration by CD3+ cells, it is reasonable to assume that tumors with high CD3 infiltration and low PDL1 expression, which portend an immune-activated state, would be linked with the best patient outcomes (Fig. 1). The gene discussed is CD274; the disease is neoplasm.